pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

470 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT800Endpoints604BioPharma Dive231onclive165Fierce Biotech74BioSpace69raps29
therapy area
allOncology81Cardiology27Psychiatry & CNS21Vaccines17Immunology17Rare Disease12Hepatology
  • Supreme Court preserves access to abortion pill by mail
    The ruling maintains access to the drug while litigation continues. Mifepristone can still be prescribed at pharmacies or by mail without requiring in-person visits.
    BioPharma Dive · 2mo ago↗ source
  • Biotech leaders campaign for Pazdur; Takeda to lay off 4,500 workers
    Hundreds of executives and investors are pushing for Rick Pazdur to be the next FDA commissioner. Elsewhere, Takeda detailed its latest restructuring and Alumis is discarding a once-highly touted i…
    BioPharma Dive · 2mo ago↗ source
  • Poll Findings Highlight the Most Anticipated GU Cancer Abstracts at ASCO 2026
    GU experts identified key abstracts of interest from the upcoming ASCO Annual Meeting via OncLive’s social media.
← prev
page 11 of 19
next →
6
Hematology6
Pulmonology5
Infectious Disease4
Ophthalmology3
Dermatology2
onclive · 2mo ago
↗ source
  • India’s pharma industry is going global. But can it catch up to China?
    A record Sun Pharma acquisition signals global ambitions. But infrastructure, capital and policy gaps could stand in the way of India becoming an R&D powerhouse.
    BioPharma Dive · 2mo ago↗ source
  • OncLive Polls Reveal Picks for Top GI Cancer Abstracts, Areas of Interest at ASCO 2026
    Polls highlighted key abstracts of interest from the upcoming ASCO Annual Meeting.
    onclive · 2mo ago↗ source
  • Prevention and Personalization Drive the Future of Oncodermatology in Melanoma
    Beth McLellan, MD, discusses radiation dermatitis prevention, scalp cooling equity, and the future of personalized oncodermatology in melanoma management.
    onclive · 2mo ago↗ source
  • AVB-001 Encapsulated IL-2 Cell Therapy Shows Safety and Immune Activity in Platinum-Resistant HGSOC
    AVB-001 was tolerable and activated CD8+ and CD4+ T cells without regulatory T-cell expansion in platinum-resistant high-grade serous ovarian carcinoma.
    onclive · 2mo ago↗ source
  • Dr Hunter on Luspatercept and Other Treatment Options for Anemia in Myelofibrosis
    Anthony M. Hunter, MD, discusses treatment decision-making for the management of anemia in myelofibrosis.
    onclive · 2mo ago↗ source
  • Dr Jones on the Protective Benefit and Tolerability of GLP-1 Agonists vs Aspirin for CRC Prevention
    Colton Jones, MD, shares data from a retrospective analysis of GLP-1 receptor agonists vs aspirin for the primary prevention of colorectal cancer.
    onclive · 2mo ago↗ source
  • IO in NMIBC, Radioligand Therapy in mHSPC Highlight Key Presentations to Watch at AUA 2026
    Ahead of the 2026 AUA Annual Meeting, GU cancer experts highlighted the abstracts that they are anticipating the most.
    onclive · 2mo ago↗ source
  • Ibrutinib Monotherapy Yields Decade-Long Durable Efficacy in Across CLL Subtypes
    Ibrutinib monotherapy produced durable efficacy over 10 years in patients with or without TP53-mutated chronic lymphocytic leukemia.
    onclive · 2mo ago↗ source
  • Imaging Clues That Raise Suspicion for Diffuse Midline Glioma
    n this episode, Dr. Chong sets up the clinical reality that patients usually present with imaging before tissue and asks Dr. Shonka how MRI findings should shape suspicion for DMG.
    onclive · 2mo ago↗ source
  • Two Diseases That Share a Name — Defining Glioblastoma and Diffuse Midline Glioma Under the 2021 WHO Classification
    In this opening episode, Dr. Shonka and Dr. Chong frame the conversation around two diseases that share the name glioma but differ fundamentally in biology, demographics, and treatment.
    onclive · 2mo ago↗ source
  • Evolving Strategies for Myelofibrosis-Associated Anemia Highlight Persistent Gaps in Biomarker Guidance
    Aaron Gerds, MD, MS, and Anthony M. Hunter, MD, break down the challenges of anemia management in myelofibrosis and potential treatment avenues.
    onclive · 2mo ago↗ source
  • Perioperative Durvalumab Plus Neoadjuvant EV Displays EFS, OS Benefits vs SOC in MIBC
    Perioperative durvalumab plus EV showed positive topline efficacy findings in MIBC.
    onclive · 2mo ago↗ source
  • Rintatolimod Plus Pembrolizumab and Cisplatin Displays 50% ORR in Recurrent Ovarian Cancer
    The addition of rintatolimod to pembrolizumab and cisplatin demonstrated robust albeit preliminary antitumor activity in patients with recurrent ovarian cancer.
    onclive · 2mo ago↗ source
  • Create Medicines raises $122M to bolster in vivo CAR-T therapies
    The fresh funds will support the biotech's pipeline of RNA-based CAR-T cell therapies for cancer and autoimmune conditions.
    BioPharma Dive · 2mo ago↗ source
  • Dana-Farber Study Finds Stage IV Breast Cancer Increasing in Incidence and Proportion Over the Last Decade
    A Dana-Farber study showed cases of stage IV breast cancer are increasing in incidence and as a proportion of all breast cancer diagnoses.
    onclive · 2mo ago↗ source
  • Biogen pushing tau drug forward despite Alzheimer’s study failure
    One of the company’s more closely watched research assets, BIIB080 is now heading to late-stage testing based on “the strength of the biomarker and efficacy data” seen in a Phase 2 trial.
    BioPharma Dive · 2mo ago↗ source
  • REVELUTION-2 Trial Is Evaluating Cardiovascular Risk With Relugolix Plus Abiraterone Acetate in High-Risk Prostate Cancer
    Sagar A. Patel, MD, discusses the REVELUTION-2 trial evaluating cardiovascular safety with hormone therapy in prostate cancer.
    onclive · 2mo ago↗ source
  • Clinical Implementation and Surveillance Strategies
    onclive · 2mo ago↗ source
  • With new data, Regenxbio to seek FDA approval of Duchenne gene therapy
    Though two serious side effects muddied the results, CEO Curran Simpson expressed optimism about a clearance and claimed FDA leadership will have a “mandate on rare disease flexibility.”
    BioPharma Dive · 2mo ago↗ source
  • Case Introduction and ctDNA as Emerging Risk Factor
    onclive · 2mo ago↗ source
  • ASCO 2026: All Eyes Are on Daraxonrasib and a Wave of Novel Targeted Therapies in GI Malignancies
    Ahead of the 2026 ASCO Annual Meeting, experts in GI malignancies share the most anticipated research being presented during the meeting.
    onclive · 2mo ago↗ source
  • MET Alterations in NSCLC: Amplification, Mutations, and Therapeutic Strategies
    Decode MET-altered lung cancer: amplification, exon 14 skipping and co-mutations, plus evolving targeted therapies and tumor board insights.
    onclive · 2mo ago↗ source